REDWOOD CITY, Calif., May 3, 2011 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced a presentation of preclinical research on its clinical stage hypoxia-activated prodrug, TH-302, at the 13th International Myeloma Workshop, being held May 3 to 6, 2011, in Paris, France. The poster presentation describes the efficacy of TH-302 when combined with bortezomib (Velcade). Bortezomib is approved for the treatment of cancer patients with multiple myeloma, a type of cancer of the bone marrow, who have already been treated with at least one other medication.
